A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Carotuximab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors TRACON Pharmaceuticals
- 29 Nov 2017 According to a TRACON Pharmaceuticals media release, first patient has been dosed.
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
- 10 Oct 2017 Status changed from not yet recruiting to recruiting.